logo
Book a meeting
VaxForm

Vax Form

Biotechnology, Po Box , Bethlehem, , 18002, Pennsylvania, 21255, United States, 1-10 Employees

vaxform.com

  • twitter
  • LinkedIn

Who is VAXFORM

VaxForm specializes in the development of vaccine formulations. Press Releases: 01Sep2020 - VaxForm was awarded a NSF SBIR Phase I grant to develop a COVID-19 vaccine using their oral del...

Read More

lock icon Get Full Access
map
  • Po Box 21255, Bethlehem, Pennsylvania, 18002, United States Headquarters: Po Box 21255, Bethlehem, Pennsylvania, 18002, United States
  • 2010 Date Founded: 2010
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from VAXFORM

VaxForm Org Chart and Mapping

Employees
Nissy Thomas

Nissy Thomas

Research Associate

Shanna Carwell

Shanna Carwell

Research Associate

Elodie Burlet

Elodie Burlet

Deputy Director

See Full Org Chart arrow
email-formate-icon
View Email Formats for VaxForm
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding VaxForm

Answer: VaxForm's headquarters are located at Po Box , Bethlehem, , 18002, Pennsylvania, 21255, United States

Answer: VaxForm's official website is https://vaxform.com

Answer: VaxForm's revenue is Under $1 Million

Answer: VaxForm's SIC: 2836

Answer: VaxForm's NAICS: 541714

Answer: VaxForm has 1-10 employees

Answer: VaxForm is in Biotechnology

Answer: VaxForm contact info: Phone number: Website: https://vaxform.com

Answer: VaxForm specializes in the development of vaccine formulations. Press Releases: 01Sep2020 - VaxForm was awarded a NSF SBIR Phase I grant to develop a COVID-19 vaccine using their oral delivery platform. 11Oct2016 - VaxForm has published the results of their non-clinical safety evaluation of their vaccine targeting S.pyogenes in the Journal of Applied Toxicology. The article citation is: Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant. Harm HogenEscha, Anisa Dunham, Elodie Burlet, Fangjia Lu, Yung-Yi C. Mosley and Garry Morefield. J Applied Toxicology 2016 01Jul2014 - VaxForm has published the results of their pre-clinical development studies for their vaccine targeting S.pyogenes in the journal Vaccine. The article demonstrates the potency and stability optimization that has been achieved during formulations development. The article citation is: Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes, Vaccine 32 (2014), pp. 3810-3815. 28May2014 - VaxForm & EMD Millipore present a poster entitled "Tangential Flow Filtration Application for the Purification and Production of S. pyogenes vaccine from E. Coli inclusion bodies" at the 2014 AAPS National Biotechnology Conference in San Diego, CA. In this work, Vaxform LLC and EMD Millipore have collaborated to develop membrane-based unit operations for the purification of inclusion bodies from a bacterial expression system. The product being purified was a recombinant fusion protein antigen targeting S. pyogenes.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access